Nihanthy Sreenath: Honored to Contribute as Faculty at a Cardio-Oncology Workshop – Oncodaily

AI News Q&A (Free Content)

Q1: What is cardio-oncology and why is it an important field in medicine?

A1: Cardio-oncology, also known as cardiovascular oncology, is an interdisciplinary field that studies the cardiovascular effects of cancer treatments, such as chemotherapy and targeted therapy. It is crucial because it addresses the molecular and clinical changes in the cardiovascular system during cancer treatment, aiming to prevent and manage heart-related side effects in cancer patients. The European Society of Cardiology has even established a council dedicated to this field, highlighting its significance.

Q2: What recent advancements have been made in the field of cardio-oncology?

A2: Recent advancements in cardio-oncology include research on the cardiotoxic effects of cancer therapies and the development of strategies to mitigate these effects. For instance, studies are focusing on the use of human induced pluripotent stem cell-derived cardiomyocytes for preclinical cancer drug cardiotoxicity testing. There is also ongoing research into the interplay between cancer and heart failure, a concept known as reverse cardio-oncology, which is an emerging theme in the field.

Q3: How is the integration of artificial intelligence being utilized in cardio-oncology?

A3: Artificial intelligence (AI) is being integrated into cardio-oncology to enhance precision medicine. AI technologies are being employed to analyze complex data sets, predict cardiotoxic risks, and personalize treatment plans for cancer patients. The American Heart Association has released scientific statements on the use of AI in cardio-oncology, emphasizing its potential to improve patient outcomes by providing more accurate and individualized care.

Q4: What was the focus of Nihanthy Sreenath's contribution at the Cardio-Oncology Workshop?

A4: Nihanthy Sreenath served as a faculty member at the Cardio-Oncology Workshop and the 6th International Conference of the Global Cancer Consortium. Her contribution focused on facilitating thoughtful discussions and meaningful exchanges at the intersection of cardiology and oncology. This engagement aimed to enhance academic learning and collaborative research in the field.

Q5: What role do clinical trials play in the development of cardio-oncology?

A5: Clinical trials are vital in cardio-oncology as they help understand and mitigate the cardiovascular risks associated with cancer treatments. These trials study the effects of anti-cancer therapies on the heart, develop strategies to prevent severe side effects like myocarditis, and refine treatment protocols. They provide crucial insights that balance effective cancer treatment with cardiovascular health, improving long-term outcomes for cancer survivors.

Q6: What are the challenges faced in engaging oncologists in cardio-oncology practice?

A6: Engaging oncologists in cardio-oncology practice presents challenges such as the need for interdisciplinary collaboration and the integration of cardiology insights into oncology care plans. There is a need to educate oncologists about the importance of cardiovascular health in cancer patients and to develop frameworks that facilitate routine cardiovascular monitoring during cancer treatment.

Q7: How is the European Society of Cardiology contributing to the field of cardio-oncology?

A7: The European Society of Cardiology contributes to cardio-oncology by providing a platform for the latest research and clinical advancements. It organizes symposiums and publishes findings that keep healthcare professionals informed about emerging challenges and opportunities in the field. This supports the development of sustainable strategies for cancer survivorship programs and enhances the integration of cardiovascular care in oncology.

References:

• Oncodaily
• Escardio
• X
• Ecrjournal
• Nih
• Iu